Several novel treatment agents for myeloproliferative neoplasms are currently being studied in phase 1 or phase 2 trials.
Researchers assessed patterns of genetic mutations and their prognostic effects in patients with primary and secondary myelofibrosis.
In this prospective study, researchers investigated the incidence of pulmonary hypertension among patients with MPNs. Their results led them to recommend systematic screening in this patient population.
An overview of the findings of an expert panel that examined the unmet clinical needs for patients with Ph-negative MPNs to assess for risks of thrombosis.
A report on oncofertility identifies the optimal multidisciplinary team for assuring that young patients with cancer can preserve their fertility and the options available to them for family building.
Due to conflicting literature, there is currently no consensus on the appropriate standard of care for managing polycythemia vera.
Certain malignancies, younger age at diagnosis, and multiple affected relatives were all associated with increased familial relative risks.
Of 5 patients with amyloid light-chain amyloidosis who received carfilzomib, all achieved very good partial response or better.
The longitudinal assessment option would allow physicians to engage with medical knowledge and resources at their own pace.
The FDA has approved Inrebic (fedratinib; Celgene) capsules to treat adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.
Cumulative incidence of acute graft-versus-host disease within 100 days of transplant was 26% in the sirolimus group and 52% in the control group.
The use of levofloxacin as prophylaxis for the prevention of neutropenic fever and bloodstream infections was associated with less disruption of the gut microbiome in patients with hematologic malignancy.
An expanded treatment protocol study sought to validate the safety and efficacy of ruxolitinib, a JAK kinase inhibitor approved by the FDA for the treatment of polycythemia vera in patients who are intolerant of, or resistant to, hydroxyurea.
Researchers identified 3 prognostic factors predictive of all-cause mortality in multivariate analyses.
Oncology nurses discuss the importance of ongoing education on the treatments, symptoms, and available information on MPNs for patients, and oncology nurses.
Patients with secondary Evans syndrome demonstrated increased mortality compared with all other cohorts.
The Food and Drug Administration (FDA) has granted Fast Track designation to nipocalimab (M281) for the prevention of hemolytic disease of the fetus and newborn (HDFN).
Oncologists are changing the way they treat, perhaps too quickly and with too little evidence — but the behavior may signal a bigger problem with how research is reported.
Overall survival of 15 years or longer was reached by 30% of patients with amyloid light-chain amyloidosis who underwent autologous stem cell transplant.
Patients with between 0, 1, 2, or 3 controlled blood counts reported similar scores on the symptom severity survey used in the study.
According to a study published in Psycho‐Oncology, patients with newly diagnosed malignant lymphoma or multiple myeloma who reported depressive symptoms prior to the start of chemotherapy had poorer survival compared with patients who were not initially depressed. The prospective analysis was conducted at the Nagoya City University Hospital in Japan. Researchers sought to investigate the…
A decrease in gait speed by 0.1 m/s was associated with increases in mortality and utilization of emergency and acute care.
Determining the type of cell infected with Epstein-Barr virus (EBV) in peripheral blood mononuclear cells (PBMCs) proves to be a valuable tool for improving the differential diagnosis of hematologic disease with concurrent EBV infection, according to study results published in Open Forum Infectious Diseases. EBV is a herpesvirus that infects approximately 90% of the population…
A total of seven evidence based interdisciplinary recommendations for management of henoch-schönlein purpura have been formulated.
Hemolytic anemia and immune thrombocytopenic purpura were the most common complications of immune checkpoint inhibitor therapy.
Pediatric essential thrombocythemia is usually low risk; watching and waiting is a feasible management approach for asymptomatic patients.
Patients with atrial fibrillation and cancer may be at higher risk for thromboembolic events.
Busulfan plus melphalan may be a viable pretreatment conditioning regimen for patients undergoing autologous hematopoietic stem cell transplantation.
Patients who developed cerebrovascular disease following allogeneic hematopoietic stem cell transplantation experienced decreased survival.
Investigators estimated the effects of immunosuppression on poor outcomes in multiple cutaneous squamous cell carcinoma.
Twitter is increasingly being used by oncologists as a tool to communicate advancements in in the treatment of cancer. What could go wrong?
Though adoptive T-cell transfer has demonstrated clinical applicability, many barriers prevent it from becoming a standard of care following transplant.
No difference was observed in relapse risk or survival between patients receiving phenytoin and patients receiving alternative antiepileptic medications.
Mechanical circulatory support (MCS) devices can lead to hemostatic events, making it crucial to include a hematologist on a patient’s MCS management team.
Adhering to mucormycosis treatment guidelines may be difficult for physicians because of the complexity of the disease.
Researchers found no evidence that neutropenic and non-neutropenic patients with sepsis should be treated differently.
Current transfusion recommendations do not adequately inform transfusion in patients with hematologic malignancies, who are increasingly treated as outpatients.
Vancomycin-resistant Enterococcus bacteremia was associated with poorer outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation.
Risk for developing active tuberculosis has not been previously assessed in patients undergoing hematopoietic cell transplantation.
Sirolimus treatment of patients undergoing allogeneic hematopoietic stem cell transplantation may prevent cytomegalovirus infection.
Non-GVHD ocular complications can seriously affect patient morbidity and quality of life following hematopoietic cell transplantation.
The risk factors of human rhinovirus lower respiratory tract infection following hematopoietic cell transplantation are not well known.
Researchers assessed risk factors for cytomegalovirus antigenemia in pediatric patients.
Patients undergoing autologous stem cell transplant are at increased risk for central line-associated bloodstream infections.
Concomitant use of aspirin and NSAIDs gives rise to a pharmcodynamic interaction that may interfere with aspirin’s antiplatelet effects.
Researchers assessed a possible association between plateletpheresis and lymphopenia when 2 platelet donors were found to have low CD4+ T-lymphocyte counts.
Recent research suggests that vitamin D deficiency may negatively influence outcomes after hematopoietic stem cell transplantation.
A single-allele mismatch was associated with decreased risk of non-relapse mortality and overall mortality compared with a single-antigen mismatch.
Though patients tended to be older at diagnosis, the severity of genetic hemochromatosis has decreased over time.
Udenyca will be supplied as 6mg/0.6mL preservative-free solution in prefilled syringes for subcutaneous injection.
The prognostic value of karyotype in systemic mastocytosis, especially in the presence of adverse mutations, is unclear.